INTRODUCTION AND OBJECTIVES: American Urological Association guidelines recommend 24-hour urine testing in the evaluation and treatment of individuals with high-risk urinary stone disease (USD). However, it remains unknown if clinicians use information from 24-hour urine testing to guide secondary prevention strategies. We sought to determine whether clinicians initiate or discontinue USD-specific medications in response to 24-hour urine testing.
INTRODUCTION AND OBJECTIVES: American Urological Association guidelines recommend 24-hour urine testing in the evaluation and treatment of individuals with high-risk urinary stone disease (USD). However, it remains unknown if clinicians use information from 24-hour urine testing to guide secondary prevention strategies. We sought to determine whether clinicians initiate or discontinue USD-specific medications in response to 24-hour urine testing.
METHODS: We used a combination of inpatient or outpatient ICD-9 code for kidney (or ureteral) stone or CPT code for receipt of a kidney (or ureteral) stone procedure to construct a national cohort of stone formers in the Veterans Health Administration between 2007 through 2013. We defined a 24-hour urine test as a 24-hour urine collection for calcium, oxalate, citrate, or sulfate. We compared rates of prescriptions of thiazide or thiazide-type diuretics, alkali therapy, and calcium salts in stone formers who completed at least one 24-hour urine collection and those who did not. We examined rates of prescriptions before and after 24-hour urine collection or initial stone diagnosis (if a stone former did not complete 24-hour urine testing). We also compared rates of prescriptions stratified by 24-hour urine results.
RESULTS: Stone formers who completed 24-hour urine testing had higher rates of prescriptions for thiazide diuretics, alkali therapy, and calcium salts following a 24-hour urine test compared to stone formers who did not complete a 24-hour urine test. Thiazide diuretics were significantly more likely to be prescribed after a 24-hour urine test in patients with hypercalciuria (13.5% increase if urine calcium > 200 mg/day; 1.8% increase if urine calcium <200 mg/day; p<0.001); alkali treatment was significantly more likely to be prescribed in patients with hypocitraturia (28.5% increase if urine citrate < 400 mg/day; 8.9% increase if urine citrate > 400 mg/day; p<0.001); and calcium salts were significantly more likely to be prescribed in stone formers even if they had hypercalciuria or lacked a diagnosis of osteopenia or osteoporosis (1.6% increase if urine calcium > 200 mg/day; 0.6% increase if urine calcium <200 mg/day; p<0.001).
CONCLUSIONS: Clinicians appear to appropriately adjust their practice patterns by increasing rates of prescription of medications that decrease USD risk in stone formers who complete 24-hour urine testing. However, opportunities exist for clinicians to reduce rates of prescription of medications that may increase stone risk (e.g. calcium salts in stone formers with hypercalciuria).
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MP08-08 ASSOCIATION BETWEEN METABOLIC SYNDROME (METS) AND KIDNEY STONE DISEASE RECURRENCE: OUTCOMES FROM A RETROSPECTIVE COHORT STUDY WITH A MEAN FOLLOW-UP OF 18-YEARS
Robert Geraghty, Sarah Prattley*, Paul Cook, Bhaskar Somani, Southampton, United Kingdom INTRODUCTION AND OBJECTIVES: There is a proven association of metabolic syndrome(MetS) and kidney stone disease (KSD). However, no one knows the risk of stone recurrence in these patients. We wanted to look at the recurrence rates in patients with MetS and whether there was an increased risk with every additional component of MetS.
METHODS: Kidney stone patients who were seen in the stone clinic between 1990e2005 and underwent detailed metabolic screening were included. Baseline data was collected on serum parameters (creatinine, bicarbonate, calcium, phosphate, parathyroid hormone (PTH)), pH and 24-hour urinary parameters (volume, creatinine, calcium, oxalate, uric acid and creatinine clearance). Other data included patient demographics, past medical history including MetS (hypertension, elevated fasting glucose, high BMI, low serum HDL and elevated triglyceride-modified NCEP ATP III). Patients were followed up in clinic and using their electronic record. Statistical analyses: one-way ANOVA and survival analysis using Cox Regression method. Survival analysis is presented as hazard ratios (HR) and a Cox regression curve.
RESULTS: A total of 256 patients with a mean age of 68 (AE14.7 years) and a male:female ratio of 179:77 underwent 7.2 (AE6.1) followups over 18 years (AE5.7 years). None of the biochemical parameters demonstrated significant results, however there was a trend towards lower pH with increasing number of MetS components. Number of patients with different MetS components are shown in table 1. The time to first stone recurrence was significantly shorter (p<0.001) with each additional baseline MetS component (Fig 1) . Each additional component 8was associated with increased HR, 2 and 4 components were significant (see table 1) .
CONCLUSIONS: Our long-term follow-up data from a dedicated stone clinic shows that the risk of first time stone recurrence increases with every additional MetS component
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INTRODUCTION AND OBJECTIVES: Kidney stone development has been linked to metabolic syndrome (MetS), which is characterized by insulin resistance. In a previous cross-sectional analysis, we reported that the homeostasis model assessment of insulin resistance (HOMA-IR) and serum insulin levels are associated with a history of kidney stones. In this prospective study, we followed the baseline cohort for 5 years. The aim of this study was to examine the impact of insulin resistance on incident kidney stones.
METHODS: A prospective cohort study was performed in 4,007 (2,084 men and 1,923 women) participants aged 35-79 years who voluntarily underwent medical examinations between April 2007 and August 2011 and were free of kidney stones. Follow-up data were obtained at 5 years after baseline examination. Insulin resistance was defined by high HOMA-IR (!2.5) or hyperinsulinemia (!15.0mU/mL). Participants with diabetes mellitus or fasting glucose !140 mg/dL at baseline were excluded. Demographic variables were compared between subjects with or without insulin resistance at baseline. Logistic regression analysis was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for incident kidney stone at 5 years after baseline. All procedures were approved by the Nagoya City University Institutional Review Board.
RESULTS: A total of 97 men (4.7%) and 45 women (2.3%) developed kidney stones at 5 years after baseline. At baseline, 48men (2.3%) and 20 women (1.0%) were diagnosed with hyperinsulinemia and Vol. 201, No. 4S, Supplement, Friday, May 3, 2019 THE JOURNAL OF UROLOGY Ò e101
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